Literature DB >> 9679042

5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine.

J R Grider1, A E Foxx-Orenstein, J G Jin.   

Abstract

BACKGROUND & AIMS: The peristaltic reflex induced by mucosal stimuli is mediated by intrinsic sensory calcitonin gene-related peptide (CGRP) neurons activated by 5-hydroxytryptamine (5-HT) released from enterochromaffin cells. The involvement of 5-HT4 receptors was examined with selective 5-HT4 agonists.
METHODS: Compartmented intestinal segments were used to measure neurotransmitter release and the mechanical components of the reflex.
RESULTS: In human jejunal and rat and guinea pig colonic segments, addition of the 5-HT4 agonist HTF 919 elicited release of CGRP only into the compartment where the 5-HT4 agonist was added; vasoactive intestinal peptide (VIP) was released only into the compartment where descending relaxation was measured, and substance P (SP) was released only into the compartment where ascending contraction was measured. The CGRP antagonist hCGRP8-37 inhibited both mechanical responses by 75%-80%. Release of CGRP, VIP, and SP as well as ascending and descending responses were inhibited by selective 5-HT4 but not by selective 5-HT3 antagonists. Similar results were obtained with a different 5-HT4 agonist, R093877. However, HTF 919 was 10-30 times more potent (median effective concentration, approximately 10 nmol/L for peptide release and 5 nmol/L for mechanical responses) than R093877.
CONCLUSIONS: Selective 5-HT4 agonists applied to the mucosa in nanomolar concentrations trigger the peristaltic reflex in human, rat, and guinea pig intestine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9679042     DOI: 10.1016/s0016-5085(98)70203-3

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  85 in total

1.  Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle.

Authors:  N H Prins; J F Van Haselen; R A Lefebvre; M R Briejer; L M Akkermans; J A Schuurkes
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  An improved in vitro bioassay for the study of 5-HT(4) receptors in the human isolated large intestinal circular muscle.

Authors:  N H Prins; N P Shankley; N J Welsh; M R Briejer; R A Lefebvre; L M Akkermans; J A Schuurkes
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

Review 3.  Small bowel review: normal physiology part 2.

Authors:  A B Thomson; M Keelan; A Thiesen; M T Clandinin; M Ropeleski; G E Wild
Journal:  Dig Dis Sci       Date:  2001-12       Impact factor: 3.199

Review 4.  Serotonergic modulating drugs for functional gastrointestinal diseases.

Authors:  Robin Spiller
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

Review 5.  Pharmacology of serotonin: what a clinician should know.

Authors:  F De Ponti
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

6.  Tegaserod in the treatment of constipation-predominant irritable bowel syndrome. Do the risks outweigh the benefits?

Authors:  Peter Wood
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-10-04       Impact factor: 3.000

7.  Pharmacological basis for the medicinal use of psyllium husk (Ispaghula) in constipation and diarrhea.

Authors:  Malik Hassan Mehmood; Nauman Aziz; Muhammad Nabeel Ghayur; Anwarul-Hassan Gilani
Journal:  Dig Dis Sci       Date:  2010-11-17       Impact factor: 3.199

8.  Gastrointestinal Motility Monitor (GIMM).

Authors:  Jill M Hoffman; Elice M Brooks; Gary M Mawe
Journal:  J Vis Exp       Date:  2010-12-01       Impact factor: 1.355

9.  Do elevated plasma vasoactive intestinal polypeptide (VIP) levels cause small intestinal motor disturbances in humans?

Authors:  Jutta Keller; Jan C Mueller-Wolf; Keihan Ahmadi-Simab; Christiane Fibbe; Ulrich Rosien; Peter Layer
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

Review 10.  5-Hydroxytryptamine (serotonin) in the gastrointestinal tract.

Authors:  Michael D Gershon
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2013-02       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.